$ONCY News

Last published 1d ago

1d agoONCYOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal CarcinomaGlobeNewswireOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carci
4d agoONCYPelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma PatientsGlobeNewswireSingle-cell sequencing demonstrates pelareorep’s ability to remodel the tumor microenvironment in a hematological cancer
4d agoONCYPelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma PatientsGlobeNewswireSAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced
1w agoONCYTranslational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven CancersGlobeNewswirePelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels more than doubled in nearly all patients after one cycle of treatment Substantial
2w agoONCYOncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven CancersGlobeNewswireGOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results for approved second-line checkpoint inhibitor monotherapy 100% of responding patients survived for
3w agoONCYOncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal CancerGlobeNewswireSAN DIEGO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the
1mo agoONCYOncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant PaymentGlobeNewswireCompletion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5 Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results
1mo agoEXEL GMAB ONCY RVMD+1Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaPR NewswireSAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with
1mo agoONCYOncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio UpdateGlobeNewswireNew method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term Three patent applications are pending, including two method
1mo agoONCY RVMD AMGN LLY+1KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034PR NewswireEquity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the...
2mo agoONCYOncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal CancerGlobeNewswirePreclinical results demonstrate pelareorep activity is maintained in the presence of RAS inhibition Findings support further evaluation of pelareorep’s potential to deepen and prolong responses to RAS-targeted therapy
2mo agoONCYOncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal CancerGlobeNewswireFDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free
3mo agoONCYOncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal CancerGlobeNewswireDesignation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track
4mo agoONCYOncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer TrialGlobeNewswireHalf of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational
5mo agoONCYOncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044GlobeNewswireIntellectual property update confirms pelareorep's unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional patent filings
5mo agoONCYOncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating OfficerGlobeNewswireSAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active
5mo agoONCYOncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted ApproachesGlobeNewswireSAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced initial data from a preclinical
5mo agoONCYFrom Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology StoryACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / May 26, 2026 / Biotech investors spend enormous amounts of time searching for "the next big thing." Most never stop to ask a more important question:What does sophisticated
5mo agoONCYOncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal TumorsGlobeNewswireSAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced translational data from the
6mo agoGTBP ONCY SNSE VIR"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesGlobeNewswireIssued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly
6mo agoONCYOncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal CancerGlobeNewswire2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in 2L RAS-Mutant MSS mCRC SAN
6mo agoONCYOncolytics Aligns with FDA on Planned Pivotal Anal Cancer StudyGlobeNewswireCompany to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient population with no
7mo agoONCYOncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal CancerGlobeNewswireSAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, an investigational, systemically
7mo agoONCYOncolytics Biotech® Completes Domicile Change to the United StatesGlobeNewswireSAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the completion of
7mo agoONCY GILD ENGN TCRX+1Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of CarePR NewswireUSANewsGroup.com News Commentary — The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by...
8mo agoONCY VIR IOVA CCCC+1Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor TypesPR NewswireEquity-Insider.com News Commentary — The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress ...
8mo agoONCY LLY GILD ACLX+1Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 BillionPR Newswirehe global oncology market is projected to nearly triple from $279.98 billion in 2026 to an estimated $748.17 billion by 2035, as immunotherapy...
8mo agoONCYOncolytics Biotech® Launches Randomized Colorectal Cancer StudyGlobeNewswireControlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS
8mo agoONCY IBRX CRSP BNTX+1Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026PR NewswireEquity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in 2025 to $170.19 billion by 2032, fueled by...
8mo agoONCY EXEL LLY MRK+1Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the ChargePR NewswireUSA News Group News Commentary, The global oncology market is on track to nearly triple in value over the next decade, growing from $279.98 billion...
8mo agoONCYOncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal CancerGlobeNewswireCompany to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate material dilution
8mo agoONCY NVCR CATX IBRX+1New Treatment Modalities Are Reaching Cancers That Resisted Everything ElsePR NewswireEquity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing...
8mo agoONCY NVCR CATX IBRX+1New Treatment Modalities Are Reaching Cancers That Resisted Everything ElsePR NewswireEquity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing...
8mo agoACRV ERAS INCY KPTI+1Registration Momentum Builds Across the Oncology PipelineGlobeNewswireVANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The FDA's accelerated approval framework continues to deliver measurable population health gains, with a January
9mo agoONCY RLAY MAIA ZLAB+1$207B Market Shift: The Race for Fast Track Approval in OncologyPR NewswireUSANewsGroup.com News Commentary – The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency issued...
9mo agoAUTL IMNM MRNA ONCY+1The $71 Billion Cancer Shift: Why The FDA Is Speeding UpGlobeNewswireVANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and
9mo agoONCYOncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal CancerGlobeNewswireStrong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant MSS mCRC with
9mo agoONCY ABBV GMAB ADCT+1$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command PremiumPR NewswireThe oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This...
9mo agoONCY PFE VSTM CATX+1$668B Oncology Surge: 5 Platforms Cracking the Code on GI TumorsPR NewswireThe global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward gastrointestinal cancers...
9mo agoONCY BNTX MAIA ACRV+1Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer TreatmentPR NewswireUSANewsGroup.com News Commentary – As the global oncology clinical trials market surges toward a projected $25.61 billion valuation by 2035[1], a...
9mo agoONCY MRNA MRK VIR+1Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer BenchmarksPR NewswireEquity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless...
9mo agoARSMF AVAI NZAUF ONCYTHE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign StackGlobeNewswireVANCOUVER, British Columbia, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Equity Insider Market Intelligence Brief – The global market has entered a cycle of defensive hardening. After a decade of aggressive speculation, the
10mo agoONCYOncolytics Biotech® Announces Results of Special Meeting of ShareholdersGlobeNewswireSAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results
10mo agoONCY NRIX ERAS FHTX+1Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent CliffPR NewswireEquity-Insider.com News Commentary – The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion toward a...
10mo agoBNTX CMPX IBRX ONCYThe $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy EraGlobeNewswireVANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by
10mo agoAVAI GHVNF ONCY QSEGF+1THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke PointsGlobeNewswireVANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – The era of abundance has reached its limit. The speculative fever of the last decade has been replaced by a
10mo agoCGON ONCY TAKOncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead BiostatisticsGlobeNewswireSAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of
10mo agoONCY CGON ZNTL AVBP+1Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026PR NewswireUSANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a...
10mo agoALLO CHRS ELVN ONCY+1The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent CliffGlobeNewswireVANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming
10mo agoONCYOncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal CancerGlobeNewswireCompared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no approved therapy SAN